Blog

Cesar Perez: During the ASCO 2024 Educational Session, we will discuss the plethora of novel agents for Head and Neck Cancer

Photo from Cesar Perez/LinkedIn

May 16, 2024, 14:31

Cesar Perez: During the ASCO 2024 Educational Session, we will discuss the plethora of novel agents for Head and Neck Cancer

Cesar Perez, Director of Drug Development at Lake Nona DDU of Florida Cancer Specialists and Research Institute, shared on LinkedIn:

“Drug Development for patients with Head and Neck Cancer has lagged behind over the last decade.

However, a new era is approaching.

During the ASCO 2024 Educational Session, we will discuss the plethora of novel agents in development for the disease, which will bring hope for a population in so much need for new options.

‘Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy’.”

Source: Cesar Perez/LinkedIn

ASCO ASCO 2024 ASCO 2024 Educational Session ASCO Annual Meeting cancer Cesar Perez Florida Cancer Specialists and Research Institute Head and Neck Cancer head and neck squamous cell carcinoma Lake Nona DDU OncoDaily Oncology PD-L1 immunotherapy

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage